3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
2
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
10
Filgrastim
7
Ifosfamide
4
Carboplatin
4
aldesleukin
3
Temozolomide
3
Peripheral Blood Stem Cell Transplantation
3
Drug Therapy
3
Docetaxel
3
Cyclophosphamide
3
Counseling
3
fludarabine phosphate
2
fludarabine
2
etoposide phosphate
2
cemiplimab
2
belinostat
2
atezolizumab
2
Thiotepa
2
Surveys and Questionnaires
2
Radiotherapy
2
Nivolumab
2
Methods
2
Metformin
2
Early Intervention, Educational
2
Doxorubicin
2
Bupropion
2
Blood Specimen Collection
2
Amifostine
2
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
2
valspodar
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Blood Component Removal
×
Gynecologic
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled